Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

This trial is for people with metastatic melanoma (skin cancer that has spread to other parts of the body) whose cancer has stopped responding to immunotherapy drugs that block PD-1 (such as pembrolizumab or nivolumab). The study is testing whether adding precise, targeted radiation to the areas of resistance can help restart the immune system's attack on the cancer. **You may be eligible if...** - You are 18 or older - You have unresectable metastatic cutaneous (skin) melanoma - You started PD-1 inhibitor immunotherapy as your first treatment - You have been on immunotherapy for at least 3 months - Your cancer has progressed or did not respond to immunotherapy - Your overall health status is good (ECOG 0–1) **You may NOT be eligible if...** - You have not yet tried immunotherapy - Your cancer is not melanoma - Your health is not good enough to tolerate radiation therapy Talk to your doctor to see if this trial is right for you.